AXSOME THERAPEUTICS INC. - COMMON STOCK

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

04 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Participate in Investor Conferences in September

27 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

21 Aug 2024 07:00:39 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

05 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5

11 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories

05 Jun 2024 07:35:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month

04 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month

03 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Participate in Upcoming Investor Conferences

30 May 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024

29 May 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting

28 May 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at Upcoming Investor Conferences

08 May 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

06 May 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Recognizes May as Mental Health Awareness Month

01 May 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting

15 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

10 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

01 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

25 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

25 Mar 2024 06:30:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

19 Mar 2024 07:00:00 By Nasdaq GlobeNewswire